A six-month subdermal implant of the opioid treatment drug buprenorphine has received Food and Drug Administration (FDA) approval, and is being seen as an enhancement of medication-assisted treatment approaches.
A six-month subdermal implant of the opioid treatment drug buprenorphine has received Food and Drug Administration (FDA) approval, and is being seen as an enhancement of medication-assisted treatment approaches.
A six-month subdermal implant of...